Metraipolis › archive › dc_80d2c823aa69

First multicenter real-world analysis of switching to next-generation enzyme replacement therapies in late-onset Pompe disease — Europe PMC PMID:41689630

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41689630
DOI
10.1007/s00415-[numero omesso]-1
License (as archived)
solo-consultazione
Archived
2026-11-05T19:57:08.075Z
SHA-256 of the archived text
c8bb5b62aabd6da2a0291010c4a91b93cf928d14c0052492be1f2313b64b8a31
Stable URL of this page
https://metraipolis.com/documento/dc_80d2c823aa69

How to cite

First multicenter real-world analysis of switching to next-generation enzyme replacement therapies in late-onset Pompe disease — Europe PMC PMID:41689630 — Europe PMC (en), https://europepmc.org/article/MED/41689630 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_80d2c823aa69 (Metraipolis archive dc_80d2c823aa69, sha256 c8bb5b62aabd6da2a0291010c4a91b93cf928d14c0052492be1f2313b64b8a31)
BibTeX
@misc{dc80d2c823aa69,
  title = {First multicenter real-world analysis of switching to next-generation enzyme replacement therapies in late-onset Pompe disease — Europe PMC PMID:41689630},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41689630},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_80d2c823aa69; sha256 c8bb5b62aabd6da2a0291010c4a91b93cf928d14c0052492be1f2313b64b8a31},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41689630. Agents can read the archived copy with the MCP tool read_document.